Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Will Moderna-NIH Patent Dispute Change Government-Industry Collaborations?

Executive Summary

US government may add provisions to future agreements to ensure its inventorship rights and make terms more favorable to the public. Lawyers say it will be difficult for Moderna to exclude NIH as co-inventor. But NIH lost a similar battle over AZT patents.

You may also be interested in...



Coronavirus Update: US To Begin Mass Vaccinations After Pfizer’s Historic Emergency Authorization

The first vaccinations are due to begin in the US, with the government extending its agreement with Moderna to bolster its vaccines supplies.

Coronavirus Update: Inside Moderna's Deal With The US

Company receives a base payment of $1.225bn for the manufacturing and delivery of the first 100 million disease, plus a bonus if mRNA-1273 reaches the market quickly.

Coronavirus Update: BARDA Funding Rises To $955m As Moderna Expands Phase III Trial

Moderna has updated its protocol, expanding its recruitment target to 30,000 and aiming for more ethnically diverse and at-risk groups to be included. 

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS145247

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel